News | Neuro Imaging | August 05, 2015

Alzheimer’s Association Launches New Website for IDEAS Study

Online resource gives information to PET facilities, patients looking to participate in landmark Alzheimer’s PET study

Alzheimer's Association, IDEAS Study, website, participation, brain PET scan

August 5, 2015 — The Alzheimer’s Association announced the launch of a new website for the upcoming Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) study. The site enables patients, caregivers, providers, and positron emission tomography (PET) facilities to get up-to-date study information, learn how to get involved and receive updates on enrollment timelines and pathways.

Site visitors will find answers to frequently asked questions and can subscribe to be notified as IDEAS information and resources become available. The site includes information for various stakeholders, including:

Patients — Study overview, patient eligibility and consent information

PET Facilities — How to get involved, basic participation requirements, reimbursement Information and locations

Referring providers — How to get involved and specialist qualifications

The IDEAS study will assess the impact of a brain PET scan to detect amyloid plaques on patient-oriented outcomes. These plaques are a core feature of Alzheimer’s disease in patients with mild cognitive impairment (MCI) or dementia of uncertain cause. Medicare will cover amyloid PET when the scan is conducted in accordance with the IDEAS-Study requirements.

IDEAS is sponsored by the Alzheimer’s Association and managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN).

For more information: www.ideas-study.org

Related Content

Researchers have developed an artificial intelligence (AI)-based brain age prediction model to quantify deviations from a healthy brain-aging trajectory in patients with mild cognitive impairment, according to a study published in Radiology: Artificial Intelligence. The model has the potential to aid in early detection of cognitive impairment at an individual level.

Flowchart showing the framework of the brain age prediction model. A, The imaging data were split into training and test datasets. The training dataset consisted of structural magnetic resonance imaging data from 974 healthy individuals, whereas the test dataset included data from 2 groups, 231 healthy controls and 224 aMCI subjects. B, A Conventional Statistical Parametric Mapping structural preprocessing pipeline was used to generate GMV maps in the MNI space. C, The intensity values from the GMV maps were extracted and concatenated to create a feature matrix that was then cleaned and normalized. D, The best elastic net model was obtained by performing supervised learning on the training dataset. To optimize the hyperparameters, a grid search was performed. E, The test dataset was input into the trained model. An age was predicted for every participant included in the test dataset. The PAD scores were calculated by subtracting the participant's chronological age from his or her predicted age. aMCI = amnestic mild cognitive impairment, GMV = gray matter volume, MNI = Montreal Neurologic Institute, Dartel = Diffeomorphic Anatomic Registrations Through Exponentiated Lie Algebra, PAD = predicted age difference. Chart courtesy of Radiological Society of North America

News | Artificial Intelligence | June 23, 2021
June 23, 2021 — Researchers have developed an...
An example of a COVID-19 pneumonia of a chest CT scan. The COVID appears as white ground glass opacities (GGOs) in the lungs. Normal lungs on CT should appear black.

An example of a COVID-19 pneumonia of a chest CT scan. The COVID appears as white ground glass opacities (GGOs) in the lungs. Normal lungs on CT should appear black.

News | Coronavirus (COVID-19) | June 23, 2021
June 23, 2021 — The Radiological Society of North America (...
Led by a Michigan Medicine physician, the research team examined treatment outcomes over two years for patients who fractured their distal radius, the larger of two bones in the forearm. They found no one-size-fits all method for treating the fracture, which more than 85,000 Medicare beneficiaries sustain annually.

Getty Images

News | Radiology Imaging | June 23, 2021
June 23, 2021 — A decade-long...
According to a new study, by the Harvey L. Neiman Health Policy Institute and the American College of Radiology’s National Mammography Database Committee, the most influential radiologist characteristics impacting mammography interpretive performance were geography, breast sub-specialization, performance of diagnostic mammography, and performance of diagnostic ultrasound.

Getty Images

News | Breast Imaging | June 23, 2021
June 23, 2021 — According to a new ...
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers | June 22, 2021
June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercia
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

Figure 1. Case example: A 54-year-old man with a history of RP+LND and a subsequent PSA of 1.25 ng/mL had no evidence of disease by baseline imaging. Piflufolastat F 18 (18F-DCFPyL)- PET/CT accurately detected biochemically recurrent prostate cancer with the PSMA PET/CT scan identifying positive left (left panel) and right peri-rectal lymph nodes (right panel).

News | Prostate Cancer | June 21, 2021
June 21, 2021 — A phase III clinica...
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Figure 1. Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included participants with clinical mild cognitive impairment and dementia. Higher rates of tau accumulation were observed in participants on the AD continuum (CU Aβ+ve and CI Aβ+ve). Participants with the highest baseline tau and rates of tau accumulation were younger and more likely to be CI Aβ+ve. Image courtesy of SNMMI

News | PET Imaging | June 16, 2021
June 16, 2021 — A novel positron emission tomography (PET
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame

Figure 1. A: COVID-19-related spatial covariance pattern of cerebral glucose metabolism overlaid onto an MRI template. Voxels with negative region weights are color-coded in cool colors, and regions with positive region weights in hot colors. B: Association between the expression of COVID-19-related covariance pattern and the Montreal Cognitive Assessment (MoCA) score adjusted for years of education. Each dot represents individual patient. C: Results of a statistical parametric mapping analysis. Upper row illustrates regions that show significant increases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the subacute stage (paired t test, p < 0.01, false discovery rate-corrected). Bottom row depicts regions that still show significant decreases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the age-matched control cohort at an exploratory statistical threshold (two-sample t test, p < 0.005). Image Credit: G Blazhenets et al., Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg

News | PET Imaging | June 16, 2021
June 16, 2021 — The effects of COVID-19 on the b